JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear …

JSH-23 is an inhibitor of NF-kB nuclear translocation. It inhibits LPS and cytokine-induced nuclear translocation of the p65 subunit of NF-kB as analyzed by EMSA and western blot. The …

In our study, we found that a novel antioxidant compound, JSH-23, plays a role in restoring bone homeostasis by scavenging intracellular ROS during both osteoclastogenesis and …

Here we have targeted the nuclear translocation of NF-κB using JSH-23 to elucidate its role in diabetic neuropathy. Methods: JSH-23 (1 and 3 mg/kg) was administered for 2 weeks in …

A cell-permeable diamino compound that selectively blocks nuclear translocation of NF-κB p65 and its transcription activity (IC 50 = 7.1 µM in a NF-κB reporter assay using RAW 264.7) …

2024年9月26日 · Results: Acute treatment with JSH-23 (10 mg/kg, intraperitoneally [ip]) led to potent anti-inflammatory effects in LPS-treated rats, including a diminished hypothermic …

The current study demonstrated that inhibiting the NF-κB signaling cascade using JSH-23 prevented depressive-like behaviors by decreasing inflammation and improving antioxidant …

JSH-23 is an inhibitor of NF-κB transcriptional activity with IC50 value of 7.1μM [1]. JSH-23 is developed to inhibit NF-κB transcriptional activity in LPS-stimulated macrophages RAW 264.7. …

2019年8月6日 · JSH-23 is a specific inhibitor of NF-κB nuclear translocation. In this study, JSH-23 exhibits inhibitory effect with an IC 50 value of 7.1 μM on NF-κB transcriptional activity in LPS …